CTLA4 and hypophysitis: In particular, among these, an immune-targeted cancer therapy-related hypophysitis has been recognized as an endocrine irAE with a higher prevalence in patients treated with anti-CTLA-4 with respect to those treated with anti-PD and anti-PD-L1 agents [7,8,9,10,11,18].